Drug Trial Radar · NCT00607386
Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy
Last checked: Nov 20, 2026Latest source record: Jun 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Dec 31, 2007
Primary completion
Jul 8, 2011
Study completion Jul 8, 2011
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- Covance; PharmaNet; PRA Health Sciences
- First posted
- Feb 5, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, up to 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to determine the safety of once weekly dosing of idursulfase 0.5 mg/kg administered by intravenous (IV) infusion for male Hunter syndrome patients ≤ 5 years old.
Conditions
- Hunter Syndrome
- Mucopolysaccharidosis II
- MPS II
Interventions
IdursulfaseBiological
Solution for intravenous infusion, 0.5 mg/kg weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety EvaluationTime frame: From the start of study treatment until 30 days after the last infusion of idursulfase, up to 53 weeks
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
Hospital de Clinicas de Porto Alegre, Servico de Genetica Medica
Porto Alegre, Rio Grande do Sul, Brazil
Instytut Pomnik Centrum Zdrowia Dziecka, Klinika Chorob Metaboliczynch, Endokrynologii i Diabetologii
Warsaw, Poland
National Taiwan University Hospital, Dept. of Pediatrics and Medical Genetics
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.